Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Entecavir dispersible tablet and its preparation process

A technology of entecavir and dispersible tablets, which is applied in the field of entecavir dispersible tablets for the treatment of hepatitis B and its preparation, and can solve the problems that many pharmaceutical factories, government departments, scientific research institutes and other institutions are conducting research work on the drug

Active Publication Date: 2006-02-15
HAINAN ZHONGHE PHARM CO LTD
View PDF0 Cites 20 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

At present, there is no dosage form of Entecavir on the market in the domestic market, but many pharmaceutical companies, government departments, scientific research institutes and other institutions are conducting research on this drug

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Entecavir dispersible tablet and its preparation process

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0023] prescription:

[0024] Entecavir 0.5g

[0025] Mannitol 25g

[0026] Microcrystalline Cellulose 137.5g

[0027] Croscarmell Starch Sodium 19g

[0028] Cross-linked polyvinylpyrrolidone 8g

[0029] Starch slurry 7g (calculated as starch)

[0030] Magnesium Stearate 3g

[0031] A total of 1000 pieces were made

[0032] Preparation:

[0033] First, the above materials were crushed through a 100-mesh sieve, and after entecavir, mannitol, and microcrystalline cellulose were fully mixed, an appropriate amount of starch slurry was added to make a soft material, granulated with a 16-mesh sieve, and dried at 60°C for 3-4 hours. Hours later, the granules were sized through a 16-mesh sieve, and the disintegrating agent cross-linked carboxymethyl starch sodium, cross-linked polyvinylpyrrolidone and lubricant magnesium stearate were added, mixed evenly, and compressed into ...

Embodiment 2

[0035] prescription:

[0036] Entecavir 0.25g

[0037] Mannitol 36g

[0038] Microcrystalline Cellulose 45g

[0039] Cross-linked sodium carboxymethyl starch 6g

[0040] Aspartame 3.6g

[0041] Lemon essence 1.2g

[0042] Talc powder 1.8g

[0043] Starch slurry 6g (calculated as starch)

[0044] A total of 1000 pieces were made

[0045] Preparation:

[0046]First, the above materials were crushed through a 100-mesh sieve, and entecavir, mannitol, and microcrystalline cellulose were thoroughly mixed, and then an appropriate amount of starch slurry was added to make a soft material, granulated with a 16-mesh sieve, and dried at 80°C for 3 hours. , 16-mesh sieve for granulation, add disintegrating agent cross-linked carboxymethyl starch sodium, flavoring agent aspartame, lemon essence, lubricant talcum powder, after mixing, press into entecavir dispersible ...

Embodiment 3

[0048] prescription:

[0049] Entecavir 2g

[0050] Xylitol 40g

[0051] Microcrystalline Cellulose 42g

[0052] Cross-linked polyvinylpyrrolidone 12g

[0053] L-HPC 6g

[0054] Polyvinylpyrrolidone 50% alcohol solution 1.8g (calculated as polyvinylpyrrolidone)

[0055] Stevioside 2.5g

[0056] Cherry essence 2.5g

[0057] PEG6000 1.5g

[0058] A total of 1000 pieces were made

[0059] Preparation:

[0060] First, the above-mentioned materials were crushed through a 100-mesh sieve, and after entecavir, xylitol, and microcrystalline cellulose were fully mixed, an appropriate amount of polyvinylpyrrolidone 50% ethanol solution was added to make a soft material, granulated through a 24-mesh sieve, and 60 After drying at ℃ for 2-3 hours, sieve the granule with 20 mesh, add disintegrating agent cross-linked polyvinylpyrrolidone, L-HPC, flavoring...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to an Entecavir dispersible tablet for treating hepatitis B and process for its preparation by using Entecavir as raw material, charging auxiliary materials of specific species and proportions, and preparing tablet through the conventional techniques in the pharmaceutical industry.

Description

technical field [0001] The invention relates to a novel pharmaceutical preparation, in particular to an entecavir dispersible tablet for treating hepatitis B and a preparation method thereof. Background technique [0002] The morbidity and mortality caused by hepatitis B virus ((HBV) in the world is the most serious among liver viruses. According to the statistics of the World Health Organization, there are about 350 million HBV carriers in the world, causing about 100-200 deaths per year At present, there are two kinds of serum vaccines and DNA recombinant vaccines for prophylaxis; and what is commonly used for therapeutic drugs is alpha-interferon, which is not only expensive and difficult to tolerate, but also has low effective rate (only 25%-40 % of patients had remission). [0003] Entecavir (entecavir) is epoxy hydroxycarbodeoxyguanosine, a deoxyguanosine analogue that can effectively inhibit the replication of hepatitis B virus, and has a strong anti-HBV effect. The...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61P1/16A61K31/522A61K9/20A61P31/20
Inventor 严轶东
Owner HAINAN ZHONGHE PHARM CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com